Lipocine (LPCN)

Revenue in 2026 (TTM): NZ$3.4 Million

According to Lipocine's latest financial reports the company's current revenue (TTM

) is NZ$3.45 Million. In 2025 the company made a revenue of NZ$3.41 Million a decrease over the revenue in the year 2024 that were of NZ$19.85 Million. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Lipocine from 2012 to 2026

Annual revenue

Year	Revenue	Change
2026 (TTM)	NZ$3.4 M	-0.23%
2025	NZ$3.41 M	-82.81%
2024	NZ$19.85 M	-540.46%
2023	-NZ$4.51 Million	-672.42%
2022	NZ$0.78 M	-96.67%
2021	NZ$23.63 M
2020	N/A	-100%
2019	NZ$0.24 M	-61.61%
2018	NZ$0.63 M
2017	N/A
2016	N/A
2015	N/A
2014	N/A
2013	N/A
2012	N/A

Revenue for similar companies or competitors

Company	Revenue	Revenue differencediff.	Country
Seagen SGEN	NZ$3.97 B	114,790.60%	🇺🇸 USA
Jazz Pharmaceuticals JAZZ	NZ$7.66 B	221,587.29%	🇮🇪 Ireland
Agile Therapeutics AGRX	NZ$37.26 M	977.21%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

Revenue for Lipocine (LPCN)

Revenue in 2026 (TTM): NZ$3.4 Million